Resmed Inc

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 120 countries. To learn more, visit ResMed.com and follow @ResMed.


Videos coming soon for Resmed Inc.
All Resmed Inc Content


Analyst Views

RMD – UBS rates the stock as Neutral

ResMed will report its first-quarter results on 30 October. UBS forecasts revenue growth for US/Canada/Latin America to be 3%. Europe and Asia are expected to show a revenue growth of 5%. Gross margin is expected to be flat versus the fourth quarter and net profit is forecast to be up 12% versus last year. 

Read More